Literature DB >> 32030305

FLOaTing toward new standards in locally advanced resectable gastroesophageal cancer.

Lorenzo Fornaro1, Caterina Vivaldi1,2, Lorenzo Calvetti3, Alessandro Cappetta3, Alfredo Falcone1,4, Giuseppe Aprile3.   

Abstract

Entities:  

Year:  2019        PMID： 32030305      PMCID： PMC6988033          DOI： 10.21037/jtd.2019.12.103

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  21 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

2.  Recent eUpdates to the ESMO Clinical Practice Guidelines on hepatocellular carcinoma, cancer of the pancreas, soft tissue and visceral sarcomas, cancer of the prostate and gastric cancer.

Authors:  G Pentheroudakis
Journal:  Ann Oncol       Date:  2019-08-01       Impact factor: 32.976

3.  Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  E C Smyth; M Verheij; W Allum; D Cunningham; A Cervantes; D Arnold
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

4.  Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.

Authors:  Yelena Y Janjigian; Francisco Sanchez-Vega; Philip Jonsson; Walid K Chatila; Jaclyn F Hechtman; Geoffrey Y Ku; Jamie C Riches; Yaelle Tuvy; Ritika Kundra; Nancy Bouvier; Efsevia Vakiani; Jianjiong Gao; Zachary J Heins; Benjamin E Gross; David P Kelsen; Liying Zhang; Vivian E Strong; Mark Schattner; Hans Gerdes; Daniel G Coit; Manjit Bains; Zsofia K Stadler; Valerie W Rusch; David R Jones; Daniela Molena; Jinru Shia; Mark E Robson; Marinela Capanu; Sumit Middha; Ahmet Zehir; David M Hyman; Maurizio Scaltriti; Marc Ladanyi; Neal Rosen; David H Ilson; Michael F Berger; Laura Tang; Barry S Taylor; David B Solit; Nikolaus Schultz
Journal:  Cancer Discov       Date:  2017-11-09       Impact factor: 39.397

5.  Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.

Authors:  Salah-Eddin Al-Batran; Ralf D Hofheinz; Claudia Pauligk; Hans-Georg Kopp; Georg Martin Haag; Kim Barbara Luley; Johannes Meiler; Nils Homann; Sylvie Lorenzen; Harald Schmalenberg; Stephan Probst; Michael Koenigsmann; Matthias Egger; Nicole Prasnikar; Karel Caca; Jörg Trojan; Uwe M Martens; Andreas Block; Wolfgang Fischbach; Rolf Mahlberg; Michael Clemens; Gerald Illerhaus; Katja Zirlik; Dirk M Behringer; Wolff Schmiegel; Michael Pohl; Michael Heike; Ulrich Ronellenfitsch; Martin Schuler; Wolf O Bechstein; Alfred Königsrainer; Timo Gaiser; Peter Schirmacher; Wael Hozaeel; Alexander Reichart; Thorsten O Goetze; Mark Sievert; Elke Jäger; Stefan Mönig; Andrea Tannapfel
Journal:  Lancet Oncol       Date:  2016-10-22       Impact factor: 41.316

6.  Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.

Authors:  Filippo Pietrantonio; Rosalba Miceli; Alessandra Raimondi; Young Woo Kim; Won Ki Kang; Ruth E Langley; Yoon Young Choi; Kyoung-Mee Kim; Matthew Guy Nankivell; Federica Morano; Andrew Wotherspoon; Nicola Valeri; Myeong-Cherl Kook; Ji Yeong An; Heike I Grabsch; Giovanni Fucà; Sung Hoon Noh; Tae Sung Sohn; Sung Kim; Maria Di Bartolomeo; David Cunningham; Jeeyun Lee; Jae-Ho Cheong; Elizabeth Catherine Smyth
Journal:  J Clin Oncol       Date:  2019-09-12       Impact factor: 44.544

Review 7.  The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.

Authors:  Emil Ter Veer; Nadia Haj Mohammad; Gert van Valkenhoef; Lok Lam Ngai; Rosa M A Mali; Maarten C Anderegg; Martijn G H van Oijen; Hanneke W M van Laarhoven
Journal:  J Natl Cancer Inst       Date:  2016-08-30       Impact factor: 13.506

8.  Predictors and Prognostic Implications of Perioperative Chemotherapy Completion in Gastric Cancer.

Authors:  Georgios Karagkounis; Malcolm Hart Squires; Marcovalerio Melis; George A Poultsides; David Worhunsky; Linda X Jin; Ryan C Fields; Gaya Spolverato; Timothy M Pawlik; Konstantinos I Votanopoulos; Edward A Levine; Carl Schmidt; Mark Bloomston; Clifford S Cho; Sharon Weber; Antonio Masi; Russell Berman; H Leon Pachter; Charles A Staley; Elliot Newman; Shishir K Maithel; Ioannis Hatzaras
Journal:  J Gastrointest Surg       Date:  2017-09-29       Impact factor: 3.452

9.  ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).

Authors:  Jens Hoeppner; Florian Lordick; Thomas Brunner; Torben Glatz; Peter Bronsert; Nadine Röthling; Claudia Schmoor; Dietmar Lorenz; Christian Ell; Ulrich T Hopt; J Rüdiger Siewert
Journal:  BMC Cancer       Date:  2016-07-19       Impact factor: 4.430

10.  ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS).

Authors:  J V Reynolds; S R Preston; B O'Neill; L Baeksgaard; S M Griffin; C Mariette; S Cuffe; M Cunningham; T Crosby; I Parker; K Hofland; G Hanna; L B Svendsen; C L Donohoe; C Muldoon; D O'Toole; C Johnson; N Ravi; G Jones; A K Corkhill; M Illsley; J Mellor; K Lee; M Dib; V Marchesin; M Cunnane; K Scott; P Lawner; S Warren; S O'Reilly; G O'Dowd; G Leonard; B Hennessy; R Mc Dermott
Journal:  BMC Cancer       Date:  2017-06-03       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.